NCT05904223 (INHALE) is a NA clinical trial of Respiratory Panel PCR Sputum in Respiratory Infection, sponsored by Alexander Zoufaly.

Who is sponsoring NCT05904223?

NCT05904223 is sponsored by Alexander Zoufaly.

What drugs are being tested in NCT05904223?

Interventions in NCT05904223: Respiratory Panel PCR Sputum.

What condition does NCT05904223 study?

NCT05904223 studies Respiratory Infection.

Is NCT05904223 still recruiting?

NCT05904223 is currently status unknown. Last updated 29 June 2023.

Last reviewed 2023-06-29 · How we verify

NCT05904223: INHALE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of IN Hospital PCR Based Assessment of Patients With Lower Respiratory Tract Infections on LEngth of Stay - INHALE Trial

Status unknown NA Last updated 29 June 2023

What this trial tests

NA trial testing Respiratory Panel PCR Sputum in Respiratory Infection in 302 participants. Status unknown.

Timeline

10 May 2023

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	Alexander Zoufaly
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	302
Start date	10 May 2023
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	1 location across Austria

Drugs / interventions tested

Respiratory Panel PCR Sputum

Conditions studied

Respiratory Infection — all drugs for Respiratory Infection →

Sponsor

Alexander Zoufaly

Who can join

18 and older, any sex, with Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

length of stay (LOS) in days
Time frame: From admission to discharge or death, whichever comes first, assessed up to 12 Months
How long is the lenght of stay in days (half-days)?

Sponsor's own description

Does the use of the BIOFIRE® FILMARRAY® Pneumonia Panel plus in hospitalized patients with lower respiratory infections lead to a reduction in length of hospital stay (LOS) and customized antibiotic treatment (higher amount of specific vs empiric treatment, shorter treatment duration, less antibiotic treatment, lower incidence of side effects) compared to the standard of care?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Respiratory Infection

Currently open trials in the same condition.

NCT06390878 — Nationwide Research on the Rewilding of Kindergarten Yards · NA · recruiting
NCT05860387 — Early Diagnosis of Invasive Lung Aspergillosis · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05904223 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexander Zoufaly
Last refreshed: 29 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05904223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing